• UGI USER
  • Jun 01, 2024
  • 7 Likes
  • 0 Comments

“PFIZER’S LORLATINIB SHOWS PROMISING RESULTS FOR ADVANCED ALK-POSITIVE LUNG CANCER”

Why in the news?

  • Pfizer’s drug Lorlatinib significantly reduces tumor progression and improves survival in advanced ALK-positive non-small cell lung cancer (NSCLC) patients.
  • Trial results show more than half of patients on Lorlatinib did not see cancer progression after five years.
source:healthline

About Non-Small Cell Lung Cancer (NSCLC):

  • Occurs when abnormal cells form and multiply in lung tissues.
  • One of two main types of lung cancer, the other being small cell lung cancer.
  • NSCLC includes a variety of lung cancers with different characteristics.

Major Types of NSCLC:

  • Adenocarcinoma: Represents about half of all lung cancer cases.
  • Squamous Cell Carcinoma (SCC): Typically originates at the tracheobronchial tree but increasingly found in the lung periphery
  • Large Cell Carcinoma: A diagnosis of exclusion, poorly differentiated.
About Pfizer:

  • Industry: Pharmaceutical and biotechnology.
  • Establishment: Founded in 1849 in New York by Charles Pfizer and Charles F. Erhart.
  • Headquarters: The Spiral, Manhattan, New York City, USA.
  • Products: Medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
  • Top Products: Pfizer–BioNTech COVID-19 vaccine, Pneumococcal conjugate vaccine, Tafamidis, etc.

Associated Article:

https://universalinstitutions.com/icmr-set-to-bring-in-evidence-based-norms-for-lung-cancer-management/